Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW Panel to Review ASKA’s Hepatic Encephalopathy Drug, Opdivo’s RCC Indication on Aug. 5
July 25, 2016
- Intractable Neurological, Psychiatric Diseases Initially Eyed for PMDA-NCNP Drug Development Guidelines
July 25, 2016
- MHLW Alerts on Use of EGFR TKIs in Opdivo-Treated Patients after 3 Deaths
July 25, 2016
- MRSA Infections Add 190 Billion Yen Annually to Medical Expenditure at DPC Hospitals: MHLW Study Group
July 25, 2016
- MHLW Advisory Panel to Discuss Novartis’s Acromegaly Drug on August 4
July 22, 2016
- MHLW Panel OKs Basic Policies for Next JP Edition, Due Out 2021
July 21, 2016
- ICH Guidelines on Multi-Regional Clinical Trials Up for Public Comments: MHLW
July 21, 2016
- Ono Issues Red Flag over Use of Immunotherapies Together with Opdivo
July 21, 2016
- PMDA to Announce Evaluation Policy on Diagnosis Using Next-Generation Sequencers
July 21, 2016
- PMDA Working Group to “Feed Back Experiences in Reviews” toward Creation of Clinical Innovation Network
July 20, 2016
- 14-Day Prescription Limit Won’t Be Eased: MHLW
July 19, 2016
- Zyprexa under PMDA Review for Risk of Drug-Induced Hypersensitivity Syndrome
July 19, 2016
- CDISC Therapeutic Area Standards “Can Be Used in Japan”: MHLW Study Group
July 19, 2016
- Generics Should Vie on “Quality and Attractiveness”: MHLW Pharma Bureau Chief
July 15, 2016
- MHLW Pharma Bureau Chief Wants to Discuss Roles of Drug Makers’ 3 Key Officers
July 15, 2016
- Certified Review Boards Will Be Required “at Around 50 Institutions” if Clinical Research Bill Passes: MHLW Director
July 15, 2016
- MHLW to Request Budgets for AMED’s Project to Promote Commercialization of Innovative Medical Seeds
July 15, 2016
- More Companies Interested in Supporting Academia Research from the Seeds Stage: AMED Official
July 14, 2016
- MHLW to Set Prerequisites for Patients, Physicians to Optimize Innovative Drug Use: Pharma Bureau Chief
July 13, 2016
- Despite Brexit, Importance of UK “Will Remain Unchanged”: Dr Suematsu of AMED
July 12, 2016
ページ
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…